Licensed to our spin-off Vaxxel, the invention relates on a proprietary recombinant hMPV strain used as a versatile live-attenuated viral vaccine platform that can express several antigens of interest. Based on the Metavac® technology, Vaxxel is developing the first intranasal bivalent vaccine candidate against human Respiratory Syncytial Virus and human Metapneumovirus.

This innovation is issued from a very fruitful collaboration with Dr. GuyBoivin’s team LVMC at the Centre de recherche du CHU de Québec-Université Laval, Vaxxel, VirNext and the laboratory VirPath. This work was supported by ANR (Agence nationale de la recherche), ANRT – Association Nationale de la Recherche et de la Technologie, Université Claude Bernard Lyon 1 EZUSLyon @LyonIngénierieProjet, Région Auvergne-Rhône-Alpes, PULSALYS, Consulat général de France à Québec, bpi, Ministère de l’enseignement supérieur, de la recherche et de l’innovation, INSERM Institut national de la santé et de la recherche médicale and CNRS – Centre national de la recherche scientifique.